HACE1, for instance, promotes malignant progression and radiotherapy resistance in glioma by competitively binding to NRF2 with KEAP1, thereby enhancing NRF2 stability and IRES‐dependent upregulation of NRF2 translation levels, leading to a significant decrease in intracellular ROS levels [51]. Here, HACE1 is linked to central nervous system cancer.